OPEN ACCESS Freely available online

Lupus: Open Access

Commentary

The Connection Between Lupus and Kidney Disease

Aisha Omar*

Department of Public Health, University of Cape Town, Cape Town, South Africa

DESCRIPTION

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects multiple organ systems, with renal involvement being one of the most serious and common complications. Lupus Nephritis (LN) refers to the inflammation of the kidneys caused by SLE, and it can lead to significant morbidity if not appropriately managed. The kidneys, being essential organs responsible for waste filtration, fluid balance, and regulation of electrolytes, can be severely compromised in patients with lupus. The kidneys in lupus patients are primarily affected by immune system dysfunction. SLE involves the production of autoantibodies, including Antinuclear Antibodies (ANA) and anti-dsDNA antibodies, which attack the body's own tissues. In lupus nephritis, these autoantibodies form immune complexes that deposit in the glomeruli, the tiny filtering units of the kidneys. The immune complex deposition triggers an inflammatory response that damages the glomeruli, leading to renal impairment. Over time, this inflammation can progress to fibrosis and scarring, ultimately compromising kidney function.

The renal involvement in lupus can manifest in a variety of ways, ranging from mild proteinuria to full-blown kidney failure. There are several subtypes of lupus nephritis, classified according to the patterns of kidney damage observed in biopsies. They are Minimal mesangial lupus nephritis, mesangial proliferative lupus nephritis, focal lupus nephritis, diffuse lupus nephritis, membranous lupus nephritis, advanced sclerosing lupus nephritis

Each varies in severity, with diffuse lupus nephritis being the most aggressive and associated with a higher risk of kidney failure. The clinical presentation of lupus nephritis can vary greatly depending on the extent and severity of kidney involvement. In some cases, patients may not exhibit any symptoms until the disease has significantly progressed. Proteinuria, presence of excess protein in the urine is a sign of kidney damage. In lupus nephritis, proteinuria is often a sign of glomerular injury. Hematuria, blood in the urine may occur as a result of glomerular damage. Edema, swelling in the legs, ankles, or around the eyes may develop due to impaired kidney function and fluid retention. Hypertension, high blood pressure is common in lupus nephritis and can be a result of both renal damage and systemic inflammation. Renal insufficiency, progressive kidney dysfunction may lead to elevated serum creatinine levels, an indicator of decreased kidney filtration.

In some cases, lupus nephritis may present with nonspecific symptoms such as fatigue, fever, and malaise, which can complicate diagnosis. Therefore, any patient with known lupus who develops new renal symptoms should be evaluated promptly. The diagnosis of lupus nephritis is primarily based on clinical signs, laboratory tests, and kidney biopsy. Routine urine tests, such as urinalysis, can reveal proteinuria and hematuria, which are indicative of renal involvement. Blood tests, including serum creatinine and Blood Urea Nitrogen (BUN), help assess kidney function. Additionally, the presence of specific autoantibodies, such as anti-dsDNA and ANA, further supports the diagnosis of lupus and lupus nephritis. However, the definitive diagnosis and classification of lupus nephritis often require a kidney biopsy. This procedure involves removing a small sample of kidney tissue for microscopic examination. The biopsy allows clinicians to assess the extent of kidney damage, classify the lupus nephritis into one of the six classes, and guide treatment decisions. Immunofluorescence and electron microscopy may also be used to detect the immune complexes within the kidney tissue.

The management of lupus nephritis involves a combination of immunosuppressive therapies and supportive measures. The goals of treatment are to control inflammation, prevent further kidney damage, and preserve kidney function. Corticosteroids, high-dose corticosteroids, such as prednisone, are typically used as the first-line treatment to reduce inflammation. These drugs are effective in managing flare-ups of lupus nephritis but come with a range of side effects, including weight gain, osteoporosis, and increased risk of infections. Immunosuppressive Agents, further suppress the immune system and reduce kidney damage, medications such as cyclophosphamide, mycophenolate mofetil, and azathioprine are often used. Cyclophosphamide is typically reserved for more severe cases of lupus nephritis, while mycophenolate mofetil has become a preferred option due to its better safety profile. Biologic Therapy, in patients with refractory

Correspondence to: Aisha Omar, Department of Public Health, University of Cape Town, Cape Town, South Africa, E-mail: aisha.omar@uct.ac.za

Received: 26-Nov-2024, Manuscript No. LOA-24-36128; **Editor assigned:** 29-Nov-2024, PreQC No. LOA-24-36128 (PQ); **Reviewed**: 13-Dec-2024, QC No. LOA-24-36128; **Revised:** 20-Dec-2024, Manuscript No. LOA-24-36128 (R); **Published:** 27-Dec-2024, DOI: 10.35248/2684-1630.24.9.331

Citation: Omar A (2024). The Connection Between Lupus and Kidney Disease. Lupus: Open Access. 9:331.

lupus nephritis, biologic agents such as rituximab (a monoclonal antibody targeting B cells) may be considered. These agents are typically used when conventional therapies fail or are not well tolerated. Antihypertensive Drugs, since hypertension is common in lupus nephritis, Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs) are frequently prescribed. These drugs help lower blood pressure and protect the kidneys from further damage. Plasma Exchange in severe cases, particularly those with rapidly progressing lupus nephritis, plasma exchange may be used to remove harmful immune complexes and antibodies from the bloodstream.

The prognosis of lupus nephritis has improved significantly over the past few decades due to advancements in diagnostic techniques and treatment options. However, the disease remains a leading cause of morbidity and mortality in lupus patients. The outcome depends on the class of lupus nephritis, the extent of kidney damage at the time of diagnosis, and the patient's response to treatment. Early detection and aggressive management are key to improving outcomes and preventing end-stage renal disease.

CONCLUSION

Renal involvement in lupus, or lupus nephritis, is a critical aspect of the disease that requires timely recognition and treatment. Due to the complex and varied nature of renal involvement, a multidisciplinary approach to care is essential to optimize patient outcomes. By focusing on early diagnosis, appropriate immunosuppressive therapy, and regular monitoring, clinicians can effectively manage lupus nephritis and reduce the risk of long-term kidney damage.